Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C40H80NO8P
CAS Number:
Molecular Weight:
734.04
MDL number:
UNSPSC Code:
51191904
NACRES:
NA.25
Product Name
14:0-18:0 PC, 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 200 mg (850446P-200mg), pkg of 1 × 25 mg (850446P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 850446P
lipid type
phospholipids
cardiolipins
shipped in
dry ice
storage temp.
−20°C
SMILES string
[O-]P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCC)=O)=O
InChI
1S/C40H80NO8P/c1-6-8-10-12-14-16-18-19-20-21-23-25-27-29-31-33-40(43)49-38(37-48-50(44,45)47-35-34-41(3,4)5)36-46-39(42)32-30-28-26-24-22-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1
InChI key
TYAQXZHDAGZOEO-KXQOOQHDSA-N
General description
Phosphatidylcholine (PC) is one of the most important constituent of colon′s mucosal layer. 14:0-18:0 PC (1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine) is an asymmetrical lipid with long alkyl side chain.
Application
14:0-18:0 PC (1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine) may be used:
- in lipid bilayers to study its miscibility with d-erythro-N-palmitoyl-sphingomyelin (16:0-SM) using differential scanning calorimetry (DSC)
- as an asymmetrical lipid component in liposomes to study the impact of bilayer area and lipid geometry and as liposomal solubilizing agents
- to prepare a low temperature-sensitive liposome for thrombolytic studies
Biochem/physiol Actions
Phosphatidylcholine (PC) forms a hydrophobic surface in the mucus by acting as a surfactant resulting in the inhibition of penetrance of bacteria.
Packaging
5 mL Amber Glass Screw Cap Vial (850446P-200mg)
5 mL Amber Glass Screw Cap Vial (850446P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Still not finding the right product?
Explore all of our products under 14:0-18:0 PC
Storage Class
11 - Combustible Solids
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joshua Owen et al.
Journal of controlled release : official journal of the Controlled Release Society, 319, 222-233 (2020-01-01)
The purpose of this exploratory study was to investigate the combination of a radiopharmaceutical, nanoparticles and ultrasound (US) enhanced delivery to develop a clinically viable therapeutic strategy for tumours overexpressing the epidermal growth factor receptor (EGFR). Molecularly targeted radionuclides have
Van Du Nguyen et al.
ACS applied materials & interfaces, 12(9), 10130-10141 (2020-02-12)
Although great efforts have been undertaken to develop a nanoparticle-based drug delivery system (DDS) for the treatment of solid tumors, the therapeutic outcomes are still limited. Immune cells, which possess an intrinsic ability to phagocytose nanoparticles and are recruited by
Bohdana Térová et al.
Biochimica et biophysica acta, 1667(2), 182-189 (2004-12-08)
In this study we have used differential scanning calorimetry (DSC) to study the miscibility of different saturated phosphatidylcholines (PCs) with D-erythro-N-palmitoyl-sphingomyelin (16:0-SM). Information about the miscibility was obtained by observing the thermotropic phase behavior of binary mixtures of saturated PCs
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 850446P-25MG | 04061835230815 |
| 850446P-200MG | 04061835230808 |